タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	エンドトキシン・自然免疫研究 19 ―新たなる基礎と臨床の架け橋―
出版社	医学図書出版
発行日	2016-11-21
著者	日本エンドトキシン・自然免疫研究会(編集) 比企直樹(編集) 谷徹(編集)
ISBN	9784865171938
ページ数	76
版刷巻号	第1版第1刷
分野	基礎医学免疫/血清
シリーズ	エンドトキシン・自然免疫研究
閲覧制限	未契約

2015年12月4日(金)、5日(土)に東京都江東区がん研有明病院吉田富三記念講堂で開催された第21回日本エンドトキシン・自然免疫研究会の講演内容をまとめた1冊。このシリーズは、エンドトキシン研究会に所属している研究者の功績を掲載してきた貴重な書籍です。

目次

表紙
閲覧
執筆者一覧
閲覧
序
閲覧
もくじ
閲覧
第1章平成27年度日本エンドトキシン・自然免疫研究会奨励賞・優秀賞
閲覧
- TLRの制御機構と新規制御因子について
第2章ランチョンセミナー
閲覧
- 外科侵襲時の免疫不全の病態と腸管免疫
第3章一般演題
閲覧
- 1. Lactobacillus gasseri JCM 1131Tの対数期におけるリポテイコ酸の局在 : Membrane vesicle表層に露出されるリポテイコ酸
- 2. Low Endotoxin Recovery ( LER ) におけるリポ多糖の形態学的変化
- 3. TLR7アゴニスト複合体の合成と活性評価
- 4. TRAF6を介したシグナル伝達とシグナル抑制に必要なIRAK - 1の構造領域
- 5. 歯周病がアルツハイマー病の分子病態ならびに認知機能障害を増悪させる機序の解明
- 6. Porphyromonas gingivalisジンジパインによるヒトマスト細胞からのIL - 31産生誘導
- 7. 横紋筋融解症性急性腎傷害におけるヘム代謝の動態～Heme Oxygenase - 1の抑制性転写因子Bach1の腎内動態～
- 8. DEP, ナノマテリアルによる細菌毒素誘発性肺傷害への悪影響
- 9. 肺癌術後の間質性肺炎に対してPMX - DHP療法を行った2症例
- 10. ポリミキシンB固定化繊維カラム ( PMX ) による血中エンドトキシン除去治療 : 細胞機能修飾の一視点
- 11. 透析患者の動脈硬化と自然炎症
御案内
閲覧
索引
索1閲覧
奥付
閲覧

参考文献

第1章平成27年度日本エンドトキシン・自然免疫研究会奨励賞・優秀賞

P.4 掲載の参考文献

1) Beutler B, Jiang Z, Georgel P, et al. : Genetic analysis of host resistance : Toll-like receptor signaling and immunity at large. Annu Rev Immunol 24 : 353-389, 2006
pubmed

2) Kaisho T, Akira S : Toll-like receptor function and signaling. J Allergy Clin Immunol 117 : 979-987 ; quiz 988, 2006
pubmed

3) Kawai T, Akira S : The role of pattern-recognition receptors in innate immunity : update on Toll-like receptors. Nat Immunol 11 : 373-384, 2010
pubmed

4) Akira S, Takeda K : Toll-like receptor signalling. Nat Rev Immunol 4 : 499-511, 2004
pubmed

5) Reuven EM, Fink A, Shai Y : Regulation of innate immune responses by transmembrane interactions : lessons from the TLR family. Biochim Biophys Acta 1838 : 1586-1593, 2014
pubmed

6) Vabulas RM, Wagner H, Schild H : Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 270 : 169-184, 2002
pubmed

7) Li M, Carpio DF, Zheng Y, et al. : An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissuerepair gene expression by necrotic cells. J Immunol l66 : 7128-7135, 2001

8) Castoldi A, Braga TT, Correa-Costa M, et al. : TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis. PLoS One 7 : e37584, 2012

9) Watanabe T, Kitani A, Murray PJ, et al. : Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 25 : 473-485, 2006
pubmed

10) Shimazu R, Akashi S, Ogata H, et al. : MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189 : 1777-1782, 1999
pubmed

11) Wakabayashi Y, Kobayashi M, Akashi-Takamura S, et al. : AProtein Associated with Toll-Like Receptor 4 (PRAT4A) Regulates Cell Surface Expression of TLR4. J Immunol 177 : 1772-1779, 2006

12) Fukui R, Saitoh S, Kanno A, et al. : Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 35 : 69-81, 2011
pubmed

13) Kusada-Funakoshi M, Sasaki J, Takada Y, et al. : Evidence that C4b-binding protein (proline-rich protein) is synthesized by hepatocytes. Biochem Med Metab Biol 45 : 350-354, 1991
pubmed

14) Dahlback B, Hildebrand B : Degradation of human complement component C4b in the presence of the C4b-binding Protein-protein S complex. Biochem J 209 : 857-863, 1983
pubmed

15) Blom AM, Kask L, Dahlback B : CCP1-4 of the C4b-binding Protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol 39 : 547-556, 2003
pubmed

16) Suankratay C, Mold C, Zhang Y, et al. : Mechanism of complement-dependent haemolysis via the lectin pathway : role of the complement regulatory proteins. Clin Exp Immunol 117 : 442-448, 1999
pubmed

17) Brodeur SR, Angelini F, Bacharier LB, et al. : C4b-Binding Protein (C4BP) Activates B Cells through the CD40 Receptor. Immunity 18 : 837-848, 2003
pubmed

18) Dahlback B : Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 261 : 12022-12027, 1986
pubmed

19) Webb JH, Blom AM, Dahlback B : Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells. J Immunol 169 : 2580-2586, 2002

20) Blom AM, Villoutreix BO, Dahlback B : Functions of human complement inhibitor C4b-binding Protein in relation to its structure. Arch Immunol Ther Exp (Warsz) 52 : 83-95, 2004
pubmed

21) Marcovina SM, Zoppo A, Vigano-D'Angelo S, et al. : Determination of serum levels of complement component C4b-binding protein : influence of age and inflammation. Int J Clin Lab Res 21 : 171-175, 1991
pubmed

22) Hayashi T, Suzuki K : LPS-Toll-Like Receptor-Mediated Signaling on Expression of Protein S and C4b-Binding Protein in the Liver. Gastroenterol Res Pract, 2010 (doi : 10. 1155/2010/189561)

23) Morita N, Yamai I, Takahashi K, et al. : C4b binding protein negatively regulates TLR1/2 response. Innate Immunity (in press)

P.13 掲載の参考文献

1) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992
pubmed

2) Bone RC : Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24 : 1125-1128, 1996

3) Bone RC : Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome : what we do and do not know about cytokine regulation. Crit Care Med 24 : 163-172, 1996

4) Takeda K, Kaisho T, Akira S : Toll-like receptors. Annu Rev Immunol 21 : 335-376, 2003
pubmed

5) Tsujimoto H, Ono S, Hiraki S, et al. : Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res 10 : 229-237, 2004
pubmed

6) Tsujimoto H, Ono S, Majima T, et al. : Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 23 : 39-44, 2005
pubmed

7) Armstrong L, Medford AR, Hunter KJ, et al. : Differential expression of Toll-like receptor (TLR) -2 and TLR-40n monocytes in human sepsis. Clin Exp Immunol 136 : 312-319, 2004

8) Brunialti MK, Martins PS, Barbosa de Carvalho H, et al. : TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. Shock 25 : 351-357, 2006
pubmed

9) Ono S, Tsujimoto H, Matsumoto A, et al. : Modulation of human leukocyte antigen-DR on monocytes and CD160n granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188 : 150-156, 2004
pubmed

10) Venet F, Tissot S, Debard AL, et al. : Decreased monocyte human leukocyte antigen-DR expression after severe burn injury : Correlation with severity and secondary septic shock. Crit Care Med 35 : 1910-1917, 2007
pubmed

11) Okamura H, Tsutsi H, Komatsu T, et al : Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 : 88-91, 1995

12) Hiraki S, Ono S, Kinoshita M, et al. : Interleukin-18 restores immune supPression in patients with nonseptic surgery, but not with sepsis. Am J Surg 193 : 676-680, 2007

13) Hiraki S, Ono S, Tsujimoto H, et al. : Neutralization of interleukin-10 or transforming growth factor-beta decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival. Surgery 151 : 313-322, 2012

14) Ramer-Quinn DS, Baker RA, Sanders VM : Activated T helper l and T helper 2 cells differentially express the beta-2-adrenergic receptor : amechanism for selective modulation of T helper l cell cytokine production. J Immunol 159 : 4857-4867, 1997

15) Sakaguchi S, Fukuma K, Kuribayashi K, et al. : Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. 1. Evidence for the active participation of T cells in natural self-tolerance ; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 161 : 72-87, 1985

16) Sakaguchi S : Regulatory T cells : key controllers of immunologic self-tolerance. Cell 101 : 455-458, 2000
pubmed

17) Monneret G, Debard AL, Venet F, et al. : Marked elevation of human circulating CD4+ CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 31 : 2068-2071, 2003
pubmed

18) MacConmara MP, Maung AA, Fujimi S, et al. : Increased CD4+ CD25+ Tregulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg 244 : 514-523, 2006

19) Nishimura H, Nose M, Hiai H, et al. : Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 : 141-151, 1999
pubmed

20) Guignant C, Lepape A, Huang X, et al. : Programmed death-11evels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 15 : R99, 2011
pubmed

21) Zhang Y, Li J, Lou J, et al. : Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 15 : R70, 2011

22) Kubo T, Ono S, Miyazaki H, et al. : Perioperative programmed death-1 expression on CD4+ T cells predicts the incidence of postoperative infectious complication. Shock 44 : 323-329, 2015
pubmed

23) Okamoto K, Fukatsu K, Hashiguchi Y, et al. : Lack of preoperative enteral nutrition reduces gut-associated lymphoid cell numbers in colon cancer patients. Ann Surg 258 : 1059-1064, 2013
pubmed

24) Marimuthu K, Varadhan KK, Ljungqvist O, et al. : A meta-analysis of the effect of combinations of immune modulating nutrients on outcome in patients undergoing major open gastrointestinal surgery. Ann Surg 255 : 1060-1068, 2012
pubmed

25) Woo TD, Oka K, Kamiya S, et al. : Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med Microbiol 60 : 1617-1625, 2011

26) Ono S, Kimura A, Hiraki S, et al. : Removal of increased circulating CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers. Surgery 153 : 262-271, 2013
pubmed

P.17 掲載の参考文献

1) Shiraishi T, Yokota S, Fukiya S, et al. : Structural diversity and biological significance of lipoteichoic acid in Gram-positive bacteria : focusing on beneficial probiotic lactic acid bacteria. Biosci Microbiota Food Health. (in press)

2) Van Driel D, Wicken AJ, Dickson MR, et al. : Cellular location of the lipoteichoic acids of Lactobacillus fermenti NCTC 6991 and Lactobacillus casei NCTC 6375. J Ultrastruct Res 43 : 483-497, 1973
pubmed

3) Granato D, Perotti F, Masserey I, et al. : Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii Lal to human enterocyte-like Caco-2 cells. Appl Environ Microbiol 65 : 1071-1077, 1999

4) Aasjord P, Grov A : Immunoperoxidase and electron microscopy studies of staphylococcal lipoteichoic acid. Acta Pathol Microbiol Scand B 88 : 47-52, 1980
pubmed

5) Hirose Y, Murosaki S, Fujiki T, et al. : Lipoteichoic acids on Lactobacillus plantarum cell surfaces correlate with induction of interleukin-12p40 production. Microbiol Immunol 54 : 143-151, 2010
pubmed

6) Haurat MF, Elhenawy W, Feldman MF : Prokaryotic membrane vesicles : new insights on biogenesis and biological roles. Biol Chem 396 : 95-109, 2015
pubmed

7) Lee EY, Choi DY, Kim DK, et al. : Gram-positive bacteria produce membrane vesicles : Proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles. Proteomics 9 : 5425-5436, 2009
pubmed

P.23 掲載の参考文献

1) Hughes PF, Thomas C, Suvarna, K, et al. : Low Endotoxin Recovery : An FDA Perspective. BioPharma Asia 4 : 14-25, 2015

2) Tsuchiya M : Possible Mechanism of Low Endotoxin Recovery. Am Pharm Rev 17 : 18-23, 2014

3) Ando T, Uchihashi T, Kodera N, et al. : High-speed AFM and nano-visualization of biomolecular processes. Pflugers Arch 456 : 211-225, 2008
pubmed

4) Brogden KA, Phillips M : The ultrastructural morphology of endotoxins and lipopolysaccharides. Electron Microsc Rev 1 : 261-278, 1988
pubmed

5) Ribi E, Anacker RL, Brown R, et al. : Reaction of endotoxin and surfactants. 1. Physical and biological properties of endotoxin treated with sodium deoxycholate. J Bacteriol 92 : 1493-1509, 1966
pubmed

6) 小林雄毅, 柴田俊生, 小柴琢己, 他 : 組換え体によるカブトガニ体凝固因子の機能解析. "エンドトキシン・自然免疫研究 18" エンドトキシン・自然免疫研究会編. 医学図書出版, 2015, p73-77

7) Bolden J, Platco C, Dubczak J, et al. : バイオ医薬品保存時間試験の分析対象物としてのエンドトキシン. JP Forum 25 : 126-134, 2016

8) Kawai T, Akira S : The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21 : 317-337, 2009
pubmed

P.27 掲載の参考文献

1) Akira S, Uematsu S, Takeuchi O : Pathogen recognition and innate immunity. Cell 124 : 783-801, 2006
pubmed

2) Kawai T, Sato S, Ishii KJ, et al. : Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5 : 1061-1068, 2004
pubmed

3) Vacchelli E, Galluzzi L, Eggermont A, et al. : Trial watch : FDA-approved TolHike receptor agonists for cancer therapy. Oncoimmunology 1 : 894-907. 2012
pubmed

4) Dockrell DH, Kinghorn GR : Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 48 : 751-755, 2001
pubmed

5) Meyer T, Surber C, French LE, et al. : Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Invest Drugs 22 : 149-159, 2013

6) Horscroft NJ, Pryde DC, Bright H : Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother 67 : 789-801, 2012
pubmed

7) Smits EL, Ponsaerts P, Berneman ZN, et al. : The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13 : 859-875, 2008
pubmed

8) Kurimoto A, Ogino T, Ichii S, et al. : Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorg Med Chem 12 : 1091-1099, 2004
pubmed

9) Lee J, Wu CC, Lee KJ, et al. : Activation of antihepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 103 : 1828-1833, 2006
pubmed

10) Wu CC, Hayashi T, Takabayashi K, et al. : Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 104 : 3990-3995, 2007
pubmed

11) Chan M, Hayashi T, Kuy CS, et al. : Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem 20 : 1194-1200, 2009
pubmed

12) Chan M, Hayashi T, Mathewson RD, et al. : Synthesis and characterization of PEGylated toll like receptor 7 ligands. Bioconjug Chem 22 : 445-454, 2011
pubmed

13) Lin G, Wang X, Yi W, et al. : A conjugate of octamer-binding transcription factor 4 and toll-like eceptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma. J Transl Med 13 : 166, 2015

14) Lynn GM, Laga R, Darrah PA, et al. : In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol 33 : 1201-1210, 2015
pubmed

15) Shinchi H, Crain B, Yao S, et al. : Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides. Bioconjug Chem 26 : 1713-1723, 2015
pubmed

P.31 掲載の参考文献

1) Janssens S, Beyaert R : Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 11 : 293-302, 2003
pubmed

2) Fujihara M, Muroi M, Tanamoto K, et al. : Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide : roles of the receptor complex. Pharmacol Ther 100 : 171-194, 2003
pubmed

3) Li S, Strelow A, Fontana EJ, et al. : IRAK-4 : a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99 : 5567-5572, 2002
pubmed

4) Kawagoe T, Sato S, Matsushita K, et al. : Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 9 : 684-691, 2008
pubmed

5) Cao Z, Xiong J, Takeuchi M, et al. : TRAF6 is a signal transducer for interleukin-1. Nature 383 : 443-446, 1996
pubmed

6) Xia ZP, Sun L, Chen X, et al. : Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461 : 114-119, 2009
pubmed

7) Li X, Commane M, Jiang Z, et al. : IL-1-induced NF-κB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK). Proc Natl Acad Sci U S A 98 : 4461-4465, 2001

8) Muroi M, Tanamoto K : IRAK-1-mediated negative regulation of Toll-like receptor signaling through proteasome-dependent downregulation of TRAF6. Biochim Biophys Acta 1823 : 255-263, 2012
pubmed

P.36 掲載の参考文献

1) Chapple IL, Genco R, Working group 2 of joint EFP/AAP workshop : Diabetes and periodontal diseases : consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol 40 : S106-112, 2013

2) Cullinan MP, Seymour GJ : Periodontal disease and systemic illness : will the evidence ever be enough? Periodontol 200062 : 271-286, 2013

3) Linden GJ, Herzberg MC, working group 4 of the joint EFP/AAP workshop : Periodontitis and systemic diseases : a record of discussions of working group 4 of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 84 : S20-23, 2013

4) Reyes L, Herrera D, Kozarov E, et al. : Periodontal bacterial invasion and infection : contribution to atherosclerotic pathology. J periodontol 84 : S30-50, 2013
pubmed

5) Schenkein HA, Loos BG : Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Clin Periodontol 40 : S51-69, 2013
pubmed

6) Galea J, Brough D : The role of infiammation and interleukin-1 in acute cerebrovascular disease. J Inflamm Res 6 : 121-128, 2013

7) Liu L, Chan C : The role of inflammasome in Alzheimer's disease. Ageing Res Rev 15 : 6-15, 2014
pubmed

8) Serpente M, Bonsi R, Scarpini E, et al. : Innate immune system and inflammation in Alzheimer's disease : from pathogenesis to treatment. Neuroimmunomodulation 21 : 79-87, 2014
pubmed

9) Fettelschoss A, Zabel F, Bachmann MF : Vaccination against Alzheimer disease : An update on future strategies. Hum Vaccin Immunother 10 : 847-851, 2014
pubmed

10) Shankar GM, Li S, Mehta TH, et al. : Amyloidbeta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 : 837-842, 2008
pubmed

11) Jonsson T, Stefansson H, Steinberg S, et al. : Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 : 107-116, 2013
pubmed

12) Akiyama H, Arai T, Kondo H, et al. : Cell mediators of infiammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14 : S47-53, 2000

13) Ridolfi E, Barone C, Scarpini E, et al. : The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration : an eye on microglia. Clin Dev Immunol 2013 (doi : 10. 1155/2013/939786)

14) Kloss CU, Kreutzberg GW, Raivich G : Proliferation of ramified microglia on an astrocyte monolayer : characterization of stimulatory and lnhibitory cytokines. J Neurosci Res 49 : 248-254, 1997

15) Marsland AL, Gianaros PJ, Abramowitch SM, et al. : Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 64 : 484-490, 2008
pubmed

16) Engelhart MJ, Geerlings MI, Meijer J, et al. : Inflammatory proteins in plasma and the risk of dementia : the rotterdam study. Arch Neurol 61 : 668-672, 2004
pubmed

17) Tobinick EL : Re : Inflammatory markers and the risk of Alzheimer disease : the Framingham Study. Neurology 70 : 1222-1223 ; author reply 1223, 2008
pubmed

18) Alvarez A, Cacabelos R, Sanpedro C, et al. : Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 28 : 533-536, 2007
pubmed

19) Holmes C, Cunningham C, Zotova E, et al. : Systemic inflammation and disease progression in Alzheimer disease. Neurology 73 : 768-774, 2009
pubmed

20) Riviere GR, Riviere KH, Smith KS : Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol 17 : 113-118, 2002
pubmed

21) Zijlstra EE, Swart GR, Godfroy FJ, et al. : Pericarditis, pneumonia and brain abscess due to acombined Actinomyces--Actinobacillus actinomycetemcomitans infection. J Infect 25 : 83-87, 1992

22) Poole S, Singhrao SK, Kesavalu L, et al. : Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J AIzheimers Dis 36 : 665-677, 2013

23) Poole S, Singhrao SK, Chukkapalli S, et al. : Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/-mice brains. J Alzheimers Dis 43 : 67-80, 2015
pubmed

24) Heneka MT, Kummer MP, Weggen S, et al. : Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res 8 : 115-131, 2011
pubmed

25) Kondo K, Niino M, Shido K : A case-control study of Alzheimer's disease in Japan--significance of life-styles. Dementia 5 : 314-326, 1994
pubmed

26) Gatz M, Mortimer JA, Fratiglioni L, et al. : Potentially modifiable risk factors for dementia in identical twins. Alzheimers Dement 2 : 110-117, 2006
pubmed

27) Oue H, Miyamoto Y, Okada S, et al. : Tooth loss induces memory impairment and neuronal cell loss in APP transgenic mice. Behav Brain Res 252 : 318-325, 2013
pubmed

P.41 掲載の参考文献

1) Pathirana RD, O'Brien-Simpson NM, Reynolds EC : Host immune responses to Porphyromonas gingivalis antigens. Periodontol 2000 52 : 218-237, 2010
pubmed

2) Steinvoll S, Halstensen TS, Schenck K : Extensive expression of TGF-β1 in chronically-inflamed periodontal tissue. J Clin Periodontal 26 : 366-373, 1999

3) Huang S, Lu F, Li J, et al. : Quantification of tryptase-TIM-3 double-positive mast cells in human chronic periodontitis. Arch Oral Biol 59 : 654-661, 2014

4) Dillon SR, Sprecher C, Hammond A, et al. : Interleukin 31, a cytokine produced by activated Tcells, induces dermatitis in mice. Nat Immunol 7 : 752-760, 2004

5) Cornelissen C, Luscher-Firzlaff J, Baron JM, et al. : Signaling by IL-31 and functional consequences. Eur J Cell Biol 91 : 552-566, 2012
pubmed

6) Imamura T, Travis J, Potempa J : The biphasic virulence activities of gingipains : activation and inactivation of host proteins. Curr Protein Pept Sci 4 : 443-450, 2003
pubmed

7) De Benedetto A, Rafaels NM, McGirt LY, et al. : Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 127 : 773-786, 2011
pubmed

8) Groeger SE, Meyle J : Epithelial barrier and oral bacterial infection. Periodontol 2000 69 : 46-67, 2015
pubmed

9) Gruber R, B6rnchen C, Rose K, et al. : Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. Am J Pathol 185 : 2777-2789, 2015

10) Cornelissen C, Marquardt Y, Czaja K, et al. : IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 129 : 426-433, 2012
pubmed

P.45 掲載の参考文献

1) Shimazu T, Yoshioka T, Nakata Y, et al. : Fluid resuscitation and systemic complications in crush syndrome : 14 Hanshin-Awaji earthquake patients. J Trauma 42 : 641-646, 1997
pubmed

2) 横田順一朗 : 16-K-2. Crush syndrome (圧挫症候群). "標準救急医学第4版" 島崎修次 (代表編集者) 編. 医学書院 2009, p450-451

3) Bosch X, Poch E, Grau JM : Rhabdomyolysis and acute kidney injury. N Engl J Med 361 : 62-72, 2009
pubmed

4) Sassa S : Biological implications of heme metabolism. J Clin Biochem Nutr 38 : 138-155, 2006

5) Nath KA, Balla G, Vercellotti GM, et al. : Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90 : 267-270, 1992

6) 1garashi K, Sun J : The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal 8 : 107-118, 2006

7) Tanioka N, Shimizu H, Takahashi T, et al. : Induction of hepatic Bachl mRNA expression by carbon tetrachloride-induced acute liver injury in rats. Biomed Rep 2 : 359-363, 2014

8) Ozono R : New biotechnological methods to reduce oxidative stress in the cardiovascular system : focusing on the Bach1/heme oxygenase-1 pathway. Curr Pharm Biotechnol 7 : 87-93, 2006
pubmed

9) Ryter SW, Tyrrell RM : The heme synthesis and degradation pathways : role in oxidant sensitivity. Heme oxygenase has both pro-and antioxidant properties. Free Radic Biol Med 28 : 289-309, 2000
pubmed

P.49 掲載の参考文献

1) Anderson PJ, Wilson JD, Hilter FC : Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease. Chest 97 : 1115-1120, 1990
pubmed

2) Renwick LC, Brown D, Clouter A, et al. : Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ Med 61 : 442-447, 2004
pubmed

3) Hussain S, Boland S, Baeza-Squiban A, et al. : Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles : role of particle surface area and internalized amount. Toxicology 260 : 142-149, 2009
pubmed

4) Inoue K, Takano H, Yanagisawa R, et al. : Effects of diesel exhaust on lung inflammation related to bacterial endotoxin in mice. Basic Clin Pharmacol Toxicol 99 : 346-352, 2006
pubmed

5) Inoue K, Takano H, Yanagisawa R, et al. : Effects of inhaled nanoparticles on acute lung injury induced by lipopolysaccharide in mice. Toxicology 238 : 99-110, 2007
pubmed

6) Inoue K, Takano H, Yanagisawa R, et al. : Effects of organic chemicals derived from ambient particulate matter on lung inflammation related to lipopolysaccharide. Arch Toxicol 80 : 833-838, 2006
pubmed

7) Inoue K, Takano H, Yanagisawa R, et al. : Effects of airway exposure to nanoparticles on lung inflammation induced by bacterial endotoxin in mice. Environ Health Perspect 114 : 1325-1330, 2006
pubmed

8) Inoue K, Takano H, Koike E, et al. : Effects of pulmonary exposure to carbon nanotubes on lung and systemic inflammation with coagulatory disturbance induced by lipopolysaccharide in mice. Exp Biol Med (Maywood) 233 : 1583-1590, 2008
pubmed

9) Inoue K, Takano H, Ohnuki M, et al. : Size effects of nanomaterials on lung inflammation and coagulatory disturbance. Int J Immunopathol Pharmacol 21 : 197-206, 2008
pubmed

10) Inoue K, Takano H, Ichinose T, et al. : Effects of Naphthoquinone on airway responsiveness in the presence or absence of antigen in mice. Arch Toxicol 81 : 575-581, 2007
pubmed

11) Misaki K, Matsui S, Matsuda T : Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons. Chem Res Toxicol 20 : 277-283, 2007
pubmed

12) Misaki K, Takamura-Enya T, Ogawa H, et al. : Tumor-promoting activity of polycyclic aromatic hydrocarbons and their oxygenated or nitrated derivatives. Mutagenesis 31 : 205-213, 2016
pubmed

P.53 掲載の参考文献

1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編 : 特発性間質性肺炎診断と治療の手引き改訂第2版. 南江堂, 2011

2) Sato T, Teramukai S, Kondo H, et al. : Impact and predictors of acute exacerbation of interstitial lung disease after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 147 : 1604-1611, 2014
pubmed

3) Sato T, Kondo H, Watanabe A, et al. : A simple risk scoring system for predicting acute exacerbation of interstitial pneumomia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 63 ; 164-172, 2015

4) Cruz DN, Antonelli M, Fumagalli R, et al. : Early use of polymyxin B hemoperfusion in abdominal septic shock : the EUPHAS randomized controlled trial. JAMA 301 : 2445-2452, 2009
pubmed

5) Kase Y, Obata T, Okamoto Y, et al. : Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther Apher Dial 12 : 374-380, 2008
pubmed

6) Kohro S, Imaizumi H, Yamakage M, et al. : Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 20 : 11-16, 2006
pubmed

7) Tsushima K, Kubo K, Koizumi T, et al. : Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J CIin Apher 17 : 97-102, 2002

8) Kushi H, Miki T, Okamoto K, et al. : Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9 : R653-661, 2005

9) 蔵原美鈴, 平松久弥子, 阿部信二, 他 : 間質性肺炎の急性増悪に対するエンドトキシン吸着療法の試み. エンドトキシン血症救命治療研会誌 9 : 224-228, 2005

10) 池田智子, 有森豊, 小野剛, 他 : 間質性肺炎の, 急性増悪に対するpolymyxin B-immobilized fiber column hemoperfusion (PMX-DHP) 療法の臨床経験. 日集中医誌 17 : 309-313, 2010

11) Hara S, Ishimoto H, Sakamoto N, et al. : Direct hemoperfusion using immobilized polymyxin B in patients with rapidly progressive interstitial pneumonias : aretrospective study. Respiration 81 : 107-117, 2011

P.56 掲載の参考文献

1) Singer M, Deutschman CS, Seymour CW, et al. : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016
pubmed

2) Nishibori M, Takahashi HK, Katayama H, et al. : Specific Removal of Monocytes from Peripheral Blood of Septic Patients by Polymyxin B-immobilized Filter Column. Acta Medica Okayama 63 : 65-69, 2009
pubmed

3) Kumagai T, Takeyama N, Yabuki T, et al. : Apheresis of activated leukocytes with an immobilized polymyxin B filer in patients with septic shock. Shock 34 : 461-466, 2010

4) Ono S, Tsujimoto H, Matsumoto A, et al. : Modulation of human leukocyte antigen-DR on monocytes and CD160n granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188 : 150-156, 2004
pubmed

5) Tsujimoto H, Ono S, Hiraki S, et al. : Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res 10 : 229-237, 2004
pubmed

6) Cantaluppi V, Assenzio B, Pasero D, et al. : Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 34 : 1638-1645, 2008
pubmed

7) Ito M, Kase H, Shimoyama O, et al. : Effects of polymyxin B-immobilized fiber using a rat cecal ligation and perforation model. ASAIO J 55 : 246-250, 2009
pubmed

8) Mitaka C, Masuda T, Kido K, et al. : Polymyxin B hemoperfusion prevents acute kidney injury in sepsis model. J Surg Res 201 : 59-68, 2016

P.60 掲載の参考文献

1) Nissen SE, Wolski K : Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 : 2457-2471, 2007
pubmed

2) Meier-Kriesche HU, Kaplan B : Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes : a paired donor kidney analysis. Transplantation 74 : 1377-1381, 2002
pubmed

3) Go AS, Chertow GM, Fan D, et al. : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296-1305, 2004
pubmed

4) Ridker PM : High-sensitivity C-reactive protein : potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 : 1813-1818, 2001
pubmed

5) Ridker PM, Rifai N, Stampfer MJ, et al. : Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy man. Circulation 101 : 1767-1772, 2000
pubmed

6) 近森正昭 : SPECTRAL社のエンドトキシン活性レベルによる腸管透過性とエンドトキシン感受性の検討. "エンドトキシン・自然免疫研究 18" 日本エンドトキシン・自然免疫研究会編. 医学図書出版株式会社, 2015, p59-64

7) Marshall JC, Foster D, Vincent JL, et al. : Diagnostic and prognostic implications of endotoxemia in critical illness : result of the MEDIC study. J Infect Dis 190 : 527-534, 2004
pubmed

8) 藤本正男, 福井博 : Endotoxin Activity Assay (EAA). "エンドトキシン・自然免疫研究 14" 日本エンドトキシン・自然免疫研究会編. 医学図書出版株式会社, 2011, p27-29

9) Cani PD, Amar J, Iglesias MA, et al. : Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 : 1761-1772, 2007
pubmed

10) Bjarnason I, Peters TJ, Wise RJ : The leaky gut of alcoholism : possible route of entry for toxic compounds. Lancet 1 : 179-182, 1984
pubmed

11) Kagan JC, Su T, Horng T, et al. : TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nat Immunol 9 : 361-368, 2008

12) Watts C : Location, location, location : identifying the neighborhoods of LPS signaling. Nat Immunol 9 : 343-345, 2008
pubmed

13) Black S, Nicolay U, Del Giudice G, et al. : Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infct Dis 213 : 1224-1228, 2016
pubmed

14) Palmer SC, Craig JC, Navaneethan SD, et al. : Benefits and harms of statin therapy for persons with chronic kidney disease : a systematic review and meta-analysis. Ann Intern Med 157 : 263-275, 2012
pubmed

15) Zinman B, Wanner C, Lachin JM, et al. : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015
pubmed

はじめての方へ

個人／法人会員登録のご案内